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Abstract
Background: Environmental epidemiology and biomonitoring studies typically rely on biological samples to assay
the concentration of non-persistent exposure biomarkers. Between-participant variations in sampling conditions of
these biological samples constitute a potential source of exposure misclassification. Few studies attempted to
correct biomarker levels for this error. We aimed to assess the influence of sampling conditions on concentrations
of urinary biomarkers of select phenols and phthalates, two widely-produced families of chemicals, and to
standardize biomarker concentrations on sampling conditions.
Methods: Urine samples were collected between 2002 and 2006 among 287 pregnant women from Eden and
Pélagie cohorts, from which phthalates and phenols metabolites levels were assayed. We applied a 2-step
standardization method based on regression residuals. First, the influence of sampling conditions (including
sampling hour, duration of storage before freezing) and of creatinine levels on biomarker concentrations were
characterized using adjusted linear regression models. In the second step, the model estimates were used to
remove the variability in biomarker concentrations due to sampling conditions and to standardize concentrations as
if all samples had been collected under the same conditions (e.g., same hour of urine collection).
Results: Sampling hour was associated with concentrations of several exposure biomarkers. After standardization for
sampling conditions, median concentrations differed by - 38 % for 2,5-dichlorophenol to +80 % for a metabolite of
diisodecyl phthalate. However, at the individual level, standardized biomarker levels were strongly correlated
(correlation coefficients above 0.80) with unstandardized measures.
Conclusions: Sampling conditions, such as sampling hour, should be systematically collected in biomarker-based
studies, in particular when the biomarker half-life is short. The 2-step standardization method based on regression
residuals that we proposed in order to limit the impact of heterogeneity in sampling conditions could be further
tested in studies describing levels of biomarkers or their influence on health.
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Background
Diesters of phthalic acid (phthalates) and some phenols
are man-made chemicals widely used in personal care
and consumer products. Some of these compounds are
endocrine-disruptors and can impact various health
outcomes in animals [1,2], which raises concern about their
potential health impacts in humans. Widespread exposure
has been documented in pregnant women [3-5], who
deserve specific consideration because of concerns on the
effects of exposure to endocrine disruptors during intra-
uterine life [6,7].
A common approach for investigating human exposure
to these compounds is the measurement of urinary
concentrations of phthalates metabolites [8] and of the
sum of concentrations of free and conjugated forms of
phenols [9].
Phthalates and phenols are non persistent compounds
in humans with a half life in non-pregnant subjects
generally estimated to be below 24 hours [10,11]. A high
day-to-day variability in their urinary concentrations has
been documented among non pregnant [12] and
pregnant [13] women, as well as within-day variations
for some phthalates metabolites [14,15] and for bisphe-
nol A (BPA) [16], but not for triclosan [17]. Other
potential sources of variability in biomarker levels that
can be seen as nuisances include duration of storage of
the biological sample at room temperature and between-
subject variations in gestational age at urine sampling or
in time elapsed since last urine void.
Making sampling conditions identical across study
participants is a way to limit this nuisance and make
biomarker levels a better proxy of short-term personal
exposure to these compounds in descriptive or etiologic
studies [18]. However, for large-scale observational stud-
ies, some degree of variation with the sampling protocol
(e.g., in hour of urine collection) is hardly avoidable for
some participants. Unless one is interested in the average
exposure of the population as a whole (in which case
maximizing variability in hour of sampling might be a
good option for quickly metabolized compounds), this
variability is a potential source of nuisance. Because
excluding participants not strictly adhering to the
sampling protocol might induce selection bias, alterna-
tive approaches allowing to statistically standardize
measured concentrations are worth investigating.
Such approaches have to our knowledge rarely been
applied. In purely descriptive studies, assayed biomarker
levels are often left untransformed. When studying the
impact of biomarker levels on health outcome, adjusting
for sampling conditions influencing biomarker levels is
sometimes performed. This approach may not be efficient
because adjusting for sampling conditions in a regression
model aiming at characterizing the effect of exposure on
disease risk is unlikely to correct for the effect of sampling
conditions on biomarker levels. As an illustration, in a
study aiming at characterizing the association between
serum concentration of 25-hydroxyvitamin D and cancer
risk where between-subject differences in season of collec-
tion of blood sample existed, Wang et al. [19] considered
several ways to handle differences in this sampling condi-
tion influencing the biomarker level. They have shown that,
because of seasonal variations in 25-hydroxyvitamin D,
choosing season-specific cut-offs to categorize the levels of
this biomarker was a more efficient approach than adjust-
ing for the date of sampling in a regression model where
cancer occurrence was the dependent variable. Choosing
season-specific cut-offs for categories of biomarker levels
fluctuating with season is, in terms of identifying the group
with the highest estimated exposure, equivalent to correct-
ing biomarker levels by a value depending on the season of
sampling. This approach has the advantage of being applic-
able independently of any information on health outcome,
e.g., in descriptive (biomonitoring) studies.
Here, we generalize this approach to the situation where
several sampling conditions are considered simultaneously,
using a 2-step standardization method based on regression
residuals. The specific objectives of our study were to
determine the influence of sampling conditions on select
phthalates metabolites and phenols urinary concentrations
among pregnant women; we then described the concentra-
tions of phthalates metabolites and phenols standardized
for sampling conditions.
Methods
Study population
We conducted a case–control study nested within Eden
[20,21] and Pélagie [22,23] mother-child cohorts
(Figure 1). These cohorts aim to study the effects of fetal
and early life events and exposures on health at birth
and later in life. Women from the Pélagie cohort
(n = 3,421) were enrolled before 19 weeks of gestation
(counted from the first day of the menstrual period)
from April 2002 to February 2006 in 3 districts of
Brittany (France). Women from the Eden cohort
(n= 2,002) were enrolled before the end of the 28th week of
gestation, from April 2003 to March 2006, at the obstetrical
departments of the University Hospitals of Nancy and
Poitiers, France. Pregnant women were followed up until
delivery, and children are being followed-up. Participants
provided informed consent for data and biological sample
collection for themselves and their offspring. These cohorts
received the approvals of the appropriate ethical commit-
tees (Comité Consultatif pour la Protection des Personnes
dans la Recherche Biomédicale, le Kremlin-Bicêtre Univer-
sity Hospital, and Commission Nationale de l’Informatique
et des Libertés). During pregnancy, women completed
questionnaires on socio-demographic characteristics, occu-
pation, and lifestyle. We performed a nested case–control
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study, including all women (n =72) who delivered boys with
external genitalia malformation identified at birth by pedia-
tricians (cases). Three women (controls) were matched to
each mother of a case for sex of the baby (i.e., male), center,
date of recruitment and gestational duration at the time of
collection of the urinary sample, corresponding to 216
controls (Figure 1)[24]. The case–control study aimed at
characterizing the impact of phthalates and phenols on
congenital malformations [25], but this report focuses on
issues related to exposure assessment.
Urine collection and analysis
For Pélagie cohort, women collected first morning urine
void at home between 6 and 19 gestational weeks, as
early as possible after recruitment, and mailed it by nor-
mal post to the research laboratory, where samples were
stored and frozen at −20°C (median storage duration at
room temperature, 2 days, Table 1). Mailed vials
contained nitric acid in order to avoid bacterial prolifera-
tion. For Eden cohort, women were asked to collect first
morning urine void at home just before the prenatal
study visit, between 24 and 30 gestational weeks, using a
polypropylene container (FP40VPS, manufactured by
CEB, Angers, France). Women who had forgotten to
bring a urine sample collected it in the hospital during
the prenatal visit. Samples were aliquoted and frozen at
−80°C (median storage duration at room temperature
4 h, Table 1). Time of urine sampling was recorded only
for women of Eden.
In 2008, frozen urine samples were shipped on dry ice
to the National Center for Environmental Health labora-
tory at the Centers for Disease Control and Prevention
(CDC) in Atlanta, Georgia (USA). The involvement of
the CDC laboratory was determined not to constitute
engagement in human subject research. Measurements
of 11 phthalate metabolites concentrations (see Add-
itional file 1: Table S1) were conducted using isotope
dilution on-line solid-phase extraction-high performance
liquid chromatography-electrospray ionization-isotope
dilution tandem mass spectrometry [26]. Molar concentra-
tions of 4 metabolites of di(2-ethylhexyl) phthalate (DEHP,
see Additional file 1: Table S1) were summed as total
DEHP (mol/l). Also, we applied correction factors of 0.66
and 0.72 to the monoethyl phthalate (MEP) and monoben-
zyl phthalate (MBzP) concentrations, respectively, because
the analytic standards used were of inadequate purity [27].
Urinary concentrations of 9 phenols were estimated
for the population of Eden only (n = 191) by using a
modification of a method involving isotope dilution on-
line SPE coupled to high-performance liquid chromatog-
raphy-tandem mass spectrometry [9]. Phenols were not
measured for the Pélagie samples because acidification
with nitric acid affected the performance of the analytical
method. Assessment of concentrations was not possible
for 1 urine sample of a control woman (urine container
broken). Total parabens (PB) concentration was
calculated by summing butyl-, ethyl-, methyl- and
propyl-paraben molar concentrations.
Statistical analysis
Imputation of missing data
Concentrations below the limit of detection (LOD) were
replaced by LOD/21/2 [28]. Missing values in sampling
time of day for Eden cohort (n = 25) were imputed using
EDEN mother-child cohort (Nancy and 
Poitiers)
1873 singleton live births 
(recruitment: 2003-2006)
PELAGIE mother-child cohort (Brittany)
3322 singleton live births 
(recruitment: 2002-2006)
1681 male newborns
24 cases of congenital anomalies 
72 controls
Total: 96 urinary assays of phthalates 
metabolites
995 male newborns
48 cases of congenital anomalies
143 controls 
Total: 191 urinary assays of phthalate 
metabolites and phenols
Study population
287 pregnant women with phthalates metabolites assays 
191 pregnant women with phenol assays (EDEN only)
Figure 1 Flow Chart of Study Population, Composed of Pregnant Women from Eden and Pélagie Cohorts, France, 2002–2006.
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Table 1 Characteristics of French Pregnant Women at the Time of Urine Sampling, and of their Offspring (Eden and
Pélagie Cohorts, 2002–2006)
Eden-Poitiers (n = 91) Eden-Nancy (n = 100) Pélagie-Brittany (n = 96) Overall (n = 287)
Characteristics
of participants
N (%) 5th-50th-95th
centiles
N (%) 5th -50th-95th
centiles
N (%) 5th -50th-95th
centiles
N (%) 5th -50th-95th
centiles
Duration of
gestationa
37-40-42 37-39-42 36-39-41 36-40-42
Age (years) 21.9-29.0-38.4 20.9-28.9-38.7 23.5-29.6-37.0 22.2-29.3-37.8
BMI b (kg/m²) 18.4-22.6-33.6 17.1-21.5-31.3 16.8-21.2-24.2 17.7-21.7-32.2
Previous livebirth
0 38 (42%) 34 (34%) 43 (45%) 115 (40%)
≥1 31 (34%) 44 (44%) 39 (41%) 114 (40%)
≥ 2 22 (24%) 22 (22%) 14 (14%) 58 (20%)
Active smoking
(>0 cig./day)c
No 74 (82%) 84 (84%) 80 (85%) 238 (83%)
Yes 17 (18%) 16 (16%) 14 (15%) 47 (17%)
Alcohol
(> 0 glasses/day)c
No 57 (70%) 71 (82%) 79 (82%) 207(78%)
Yes 24 (30%) 16 (18%) 17 (18%) 57 (22%)
Maternal
education
High school
or less
51 (58%) 44 (45%) 38 (40%) 133 (48%)
High school
+ 2 years
or more
37 (42%) 53 (55%) 58 (60%) 148 (52%)
Occupation b
No 31 (34%) 27 (27%) 12 (12%) 70 (25%)
Yes 59 (66%) 72 (73%) 84 (88%) 215 (75%)
Date of urine
sampling
Jul. 03- Nov. 04d-
Aug. 05
Dec.03- Sept.04d-
Jan.06
Aug. 02- Nov. 03d-
Mar. 05
Mar. 03- Jun. 04d-
Nov. 05
Urine Sampling
conditions
Time of
sampling
Before 7.00 AM 12 (18%) 23 (23%) - 35 (21%)
7.00 to 7.59 AM 29 (44%) 44 (44%) - 73 (44%)
8.00 to 9.59 AM 13 (20%) 27 (27%) - 40 (24%)
After 10.00 AM 12 (18%) 6 (6%) - 18 (11%)
Creatinine (g/l) 0.46-1.04-2 0.38-1.16-2.30 0.47-1.10-2.1 0.43-1.10-2.20
Gestational weeks
at sampling
25-27-28.6 24.1-26.4-28.5 7.4-13-16.9 9.1-25.6-28.3
Duration of
storage at room
temperature (h)
0.7-3-6 3-5-8 24-48-168 1-5-120
Season of sampling
Jan-March 27 (30%) 32 (32%) 24 (25%) 83 (29%)
April-June 22 (24%) 27 (27%) 31 (32%) 80 (28%)
July-Sept 21 (23%) 17 (17%) 21 (22%) 59 (20%)
Oct-Dec 21 (23%) 24 (24%) 20 (21%) 65 (23%)
Day of sampling
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linear regression adjusted for date and sampling season,
parity, education level, occupation, active smoking and
center. When it was used as an adjustment factor,
sampling time was assumed to be 7:00 A.M. for women
of Pélagie; models describing the influence of sampling
time on biomarker concentrations were estimated
excluding Pélagie subjects.
Correction for case–control sampling
To make the distribution of biomarker concentrations
relevant for the source population (i.e., mothers of
male newborns from our cohorts), we corrected for the
over-representation of cases induced by our case–control
design using a reweighing approach [29]. Center-specific
weights corresponded to the inverse of the inclusion
probability of controls, so as to give cases and controls the
same relative weight than in the original cohorts (about 1
case for 37 male newborns). Unless otherwise specified, this
correction was applied in all regression models.
Standardization for sampling conditions
We used a 2-step standardization method based on
regression residuals to standardize biomarker levels on
sampling conditions, that is, to limit the impact of
between-subject variations in sampling conditions. The
principle is to take away from the observed biomarker
concentration a value depending on how much the
sampling conditions for subject i differ from the stand-
ard sampling conditions, i.e. those that should have been
observed for all subjects in ideal conditions. This 2-step
standardization method is detailed in the Additional file
2 statistical appendix and outlined below:
First step of standardization: Influence of sampling
conditions on biomarker concentrations: The first step
consists in a description of the association between
sampling conditions and the level of each biomarker,
adjusted for potential confounders. Sampling conditions
considered were hour, season and day of sampling,
gestational age at collection, duration of storage of
urine sample at room temperature before freezing (in
multiples of 24 hours for Pélagie cohort where sampling
hour was unknown). We also considered urinary
creatinine concentration, seen as a marker of urinary
dilution. Creatinine also depends on individual or
behavioral characteristics such as muscle mass, and
authors have proposed to use specific gravity as a more
relevant marker of urinary dilution [13,30]; however
this parameter was not available in our study.
The association of sampling conditions with the log-
transformed concentration ln([Conc]) = Y of each
compound was studied using linear regression models
adjusted for all sampling conditions simultaneously
(measurement models). Since individual characteristics
were possibly associated to sampling conditions and
biomarker concentrations, measurement models were
further adjusted for maternal age, body mass index
before pregnancy, parity, education, current occupation,
active smoking, year of sampling and center.
Second step of standardization for sampling conditions:
Using the estimated parameters of the measurement
models, we predicted the concentrations that would
have been observed assuming that all samples had been
collected under the same standard conditions. These
conditions were assumed to correspond to the median
values for hour of sampling (7:30 A.M.), urinary
creatinine concentration (1.2 g/l), and time elapsed
between sample collection and freezing (5 hours); the
day of sampling was assumed to be Monday, the
trimester of sampling April-June and the gestational age
at collection was assigned as the category
corresponding to between 6 and 10 gestational week in
Pélagie cohort and to between 24 and 25 week in Eden
cohort. For each biomarker, this standardized
concentration ([Conci]standardized) was estimated from
the measured concentration [Conci]measured in each
subject i using formula (1):
lnð Conci
 standardized
ÞÞ ¼ lnð Conci
 measured
Þ
–
X
j
βsamp cond j  ðXj
i
−Xj
stdÞ
 
1ð Þ
where βsamp cond j is the regression parameter
quantifying the effect of sampling condition j on the
biomarker’s concentration, as estimated in the above-
defined measurement model, Xj
i corresponds to the
value of this condition for subject i, and Xj
std
corresponds to the chosen standard value for sampling
Table 1 Characteristics of French Pregnant Women at the Time of Urine Sampling, and of their Offspring (Eden and
Pélagie Cohorts, 2002–2006) (Continued)
Monday to Friday 91
(100%)
100
(100%)
82 (85%) 273(95%)
Saturday or
Sunday
0 (0%) 0 (0%) 14 (15%) 14 (5%)
a Gestational duration (weeks) at delivery.
b Before pregnancy.
c During pregnancy.
d Median value. November 2004 means that half of the urine samples were collected after November 2004.
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condition j. This formula is justified in the Additional
file 2 statistical appendix.
Finally, relative variations between median measured and
standardized biomarker concentrations were calculated. All
calculations were conducted using Stata/SE 10.0.
Results
The study included 287 pregnant women (Table 1,
Figure 1). Eight of the 11 phthalates metabolites and 5
of the 9 phenols were detected in at least 95 % of the
population (see Additional file 1: Table S1). Pearson
coefficients of correlation between log-transformed
biomarker levels were below 0.70, but for the
correlations between 2,4-Dichlorophenol (2,4-DCP)
and 2,5-DCP (Pearson correlation coefficient of 0.87)
and between mono-n-butyl phthalate (MBP) and
mono-3-carboxypropyl phthalate (MCPP, correlation
0.76; see Additional file 1: Table S2).
Sampling conditions and phthalates biomarkers
MBP and MCPP had significantly lower concentrations
after 2005 than in 2003–2004, while for mono carbox-
yoctyl phthalate (MCOP) concentrations increased with
sampling year. Concentrations of phthalates metabolites
tended to decrease with maternal age, in particular for
mono-isobutyl phthalate (MiBP). A higher educational
level was associated with lower concentrations of MiBP,
MBzP and MCOP (see Additional file 1: Table S3).
For Eden cohort, 95 % of urine samples were collected
before 10:30 AM. Apart from MEP, phthalates metabo-
lites concentrations tended to decrease with increasing
sampling hour (adjusted P≤ 0.05 for metabolites of
DEHP, MBP, MCPP, mono carboxynonyl phthalate
(MCNP) and MCOP, Table 2). Concentrations of all
phthalates metabolites increased with urinary creatinine
level. Gestational age at sampling was not associated
with the urinary concentrations of phthalates metabo-
lites. Only the concentration of MBP decreased with the
time elapsed between sample collection and freezing. No
phthalate metabolite was associated with either day or
season of sampling (Table 2).
Sampling conditions and phenols biomarkers
A higher educational level was associated with higher
parabens concentration (see Additional file 1: Table S4).
Sampling hour was negatively associated with BPA
concentration (Table 3). Urinary creatinine was positively
associated with the concentrations of all phenols but
triclosan. BPA concentration increased with gestational
age at sampling. It tended to increase with the duration
of sample storage at room temperature (Table 3).
Standardization of biomarker concentrations on sampling
conditions
Table 4 shows the relative change in biomarker concen-
trations corrected for case–control sampling: after an
additional standardization for sampling conditions, the
strongest relative variations were observed for the
concentrations of MCNP, for the metabolites of DEHP
and MCOP (+80 %, +56 % and +44 %, respectively);
median phenols concentrations varied between −38 % for
2,5-DCP and +15 % for BPA. The correlation coefficients
between log-transformed biomarker levels before and
after standardization ranged between 0.88 for MBzP and
0.99 (P< 0.01) for triclosan (Table 4).
Discussion
Within our population of pregnant women, the hour of
urine collection (in the morning) was negatively asso-
ciated with the concentration of most metabolites of
phthalates (apart from MEP) and also of BPA (a result
based on Eden cohort only). Standardization for sam-
pling conditions modified the median concentrations by
−38 % for 2,5-DCP up to +80 % for MCNP, but standar-
dized levels were relatively strongly correlated with
unstandardized ones (correlation coefficients ranged
between 0.88 for MBzP to 0.99 for triclosan).
Concentrations of some phthalate metabolites and of
BPA decreased with increasing hour of collection in the
morning. These changes may be due to exposure being
more frequent at specific hours of the day (e.g. during
the evening meal and less frequently in the night and
early morning), and to the toxicokinetics of phthalates
and phenols in each individual. In the case of Bisphenol
A, for example, Teeguarden et al concluded that spot
urine samples reflect exposure in the prior meal, or prior
4- to 6-hour period, but not during the whole 24-hour
period preceding urine sampling [31]. Other studies in
observational settings reported strong variations in
biomarker urinary levels throughout the day [14,16]. We
found no relation between gestational age at sampling
and phthalates concentration. However, our study design
had limitations to investigate this relation because we
examined 2 distinct and relatively short periods of gesta-
tion for phthalates metabolites concentrations and only 1
for phenols concentrations, so that variability in
sampling week was limited.
The decrease in the concentrations of MBP with the
increasing duration of storage of urine samples at room
temperature could be explained by microbial degradation
or by irrecoverable adsorption of the monoesters meta-
bolites to other urinary components or sediments [32].
The overlap between the 2 cohorts in the distributions of
duration of storage was limited, so that the estimate of
the influence of storage duration is mostly based on
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Table 2 Adjusted Association Between Log-Transformed Phthalate Monoester Metabolites Urinary Concentrations and Sampling Conditions among French
Pregnant Women From Eden and Pélagie Cohorts, 2002–2006 a
DEHP metaboliteshh MiBP MBP MCPP MBzP MEP MCNP MCOP
Sampling conditions n β P, p trend β P, p trend β P, p trend β P, p trend β P, p trend β P, p trend β P, p trend β P, p trend
Hour of sampling 191 .02f, <.01g .29 f, .08g <0.01f ,g .04 f, .03g .06 f, .13g .66 f, .71g .12 f, .22g .32 f, .16g
< 7.00 AM 36 0 0 0 0 0 0 0 0
7.00 to 7.59 AM 75 0.00 0.99 −0.18 0.44 −0.29 0.22 0.04 0.86 0.33 0.28 −0.29 0.24 0.26 0.30 0.08 0.73
8.00 to 9.59 AM 59 −0.39 0.09 −0.27 0.31 −0.51 0.05 −0.08 0.71 −0.09 0.78 −0.21 0.46 −0.16 0.58 −0.20 0.39
After 10.00 AM 21 −0.80 0.03 −0.63 0.06 −1.08 <0.01 −0.88 <0.01 −0.68 0.09 −0.11 0.77 −0.53 0.29 −0.39 0.23
Continuous b −0.09 0.04 −0.06 0.22 −0.20 <0.01 −0.10 0.02 −0.09 0.09 −0.03 0.62 −0.12 0.05 −0.09 0.05
Creatinine(g/l)c 287 1.1 <0.01 0.98 <0.01 0.96 <0.01 0.95 <0.01 1.2 <0.01 0.96 <0.01 0.76 <0.01 0.91 <0.01
Gestational age (weeks)
Pélagie cohort 96 .92 f, .56g .61 f, .34g .74 f, .52g .02 f, .52g .28 f, .24g .23 f, .47g .29 f, .11g .48 f, .36g
6-10 24 0 0 0 0 0 0 0 0
10-12 20 0.03 0.94 −0.009 0.98 0.16 0.60 0.82 0.01 −0.27 0.45 −0.26 0.56 −0.24 0.47 0.31 0.42
12-14 41 0.06 0.84 0.37 0.29 0.33 0.28 0.21 0.48 0.26 0.44 0.35 0.27 −0.29 0.38 −0.10 0.78
14-19 11 0.29 0.56 0.10 0.75 0.06 0.87 −0.04 0.91 0.22 0.63 −0.20 0.60 −0.76 0.07 −0.20 0.62
Continuous d −0.01 0.76 0.02 0.67 0.01 0.74 −0.008 0.84 0.05 0.36 0.03 0.54 −0.07 0.17 −0.04 0.42
Eden cohort 191 .50 f, .30g .25 f, .58g .14 f, .09g .18 f, .08g .01 f, .43g .67 f, .95g .15 f, .36g .63 f, .38g
24-25 25 0 0 0 0 0 0 0 0
25-27 87 −0.06 0.75 −0.27 0.23 0.01 0.97 0.05 0.82 −0.58 0.03 −0.22 0.44 −0.20 0.57 −0.02 0.94
27-30 79 0.13 0.48 −0.01 0.96 0.38 0.21 0.33 0.14 −0.06 0.84 −0.10 0.74 0.15 0.68 0.14 0.49
Continuous d 0.03 0.55 0.04 0.50 0.14 0.04 0.11 0.07 0.07 0.35 −0.007 0.93 0.07 0.35 0.02 0.79
Day of sampling 287 0.31 f 0.40 f 0.96 f 0.61 f 0.18 f 0.11 f 0.05 f 0.44 f
Monday 57 0 0 0 0 0 0 0 0
Tuesday 69 −0.37 0.14 −0.17 0.42 0.04 0.86 −0.11 0.54 0.02 0.93 −0.02 0.92 −0.29 0.19 −0.20 0.33
Wednesday 65 −0.10 0.64 −0.27 0.11 −0.0005 0.99 −0.24 0.20 −0.06 0.81 −0.04 0.88 −0.45 0.02 −0.39 0.03
Thursday 48 −0.33 0.13 −0.18 0.39 −0.14 0.49 −0.36 0.11 −0.11 0.60 −0.22 0.36 −0.10 0.73 −0.30 0.17
Friday 34 −0.28 0.25 −0.40 0.04 0.14 0.61 −0.10 0.73 −0.53 0.04 −0.25 0.38 −0.45 0.02 −0.47 0.08
Saturday 7 −0.41 0.17 −0.04 0.88 0.05 0.85 −0.42 0.19 0.06 0.85 −0.92 <0.01 −0.63 0.03 −0.57 0.16
Sunday 7 0.17 0.46 0.17 0.64 −0.19 0.57 −0.40 0.21 0.42 0.22 −0.47 0.20 −0.18 0.48 −0.38 0.22
Season of sampling 287 0.54 f 0.34 f 0.92 f 0.86 f 0.52 f 0.84 f 0.81 f 0.98 f
Jan-March 83 0 0 0 0 0 0 0 0
April-June 80 −0.05 0.79 −0.12 0.49 0.08 0.65 −0.10 0.55 −0.06 0.75 −0.12 0.56 0.005 0.98 0.07 0.70
July-Sept 59 −0.15 0.47 −0.12 0.57 −0.004 0.98 −0.07 0.71 0.21 0.35 0.06 0.82 0.10 0.63 0.06 0.79
Oct-Dec 65 −0.33 0.15 −0.38 0.07 0.12 0.62 −0.17 0.42 −0.17 0.52 −0.07 0.76 −0.10 0.65 0.03 0.90
287 .29 f, .30g .38 f, .29g .82 f, .66g .83 f, .58g .30 f, .27g .51 f, .95g .85 f, .97g .24 f, .38g
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9
Table 2 Adjusted Association Between Log-Transformed Phthalate Monoester Metabolites Urinary Concentrations and Sampling Conditions among French
Pregnant Women From Eden and Pélagie Cohorts, 2002–2006 a (Continued)
Duration of urine storage at
room temperature (hours)
≤ 3 57 0 0 0 0 0 0 0 0
3-5 84 −0.22 0.33 0.29 0.18 0.23 0.34 0.09 0.63 −0.006 0.99 0.18 0.49 −0.22 0.43 −0.12 0.58
6-24 94 −0.01 0.96 0.13 0.58 0.16 0.57 0.21 0.36 −0.09 0.80 −0.21 0.57 −0.20 0.57 −0.23 0.39
> 24 52 −0.35 0.34 0.35 0.26 0.19 0.60 0.20 0.51 0.39 0.38 0.0005 0.99 −0.05 0.91 0.21 0.55
Continuous e −0.002 0.11 −0.002 0.21 −0.002 0.05 0.0003 0.86 0.0007 0.69 0.0004 0.81 −0.001 0.36 0.001 0.43
We applied correction factors of 0.66 and 0.72 to the monoethyl phthalate (MEP) and monobenzyl phthalate (MBzP) concentrations, respectively, because the analytic standards used were of inadequate purity.
a Linear regression models were corrected for over-representation of cases and adjusted for maternal age, BMI, parity, centre, education, occupation and urine sampling conditions.
b Regression parameters are given for an increase by 1 in the sampling hour.
c Regression parameters are given for an increase by 1 g/l in urinary creatinine concentration.
d Regression parameters are given for an increase by 1 week.
e Regression parameters are given for an increase by 1 hour.
f
P of heterogeneity test.
g
P of trend test based on the indicated categories.
h DEHP metabolites: MEHHP+MEOHP+MECPP +MEHP.
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9
subjects from Eden cohort for durations shorter than
24 h, and on subjects from Pélagie cohort for durations
of 24 h or more. The increasing concentration of BPA
with increasing duration of storage at room temperature
was unexpected; it might be due to a leakage of BPA
from the plastic containers (or their caps) used to collect
urine samples, as might happen if some women had used
polycarbonate containers instead of the polyprolene
containers planned for the study. Our analysis allowed to
identify this potential issue and the statistical approach
used attempted to correct for any resulting error.
The decrease in urinary concentrations of MBP, a
metabolite of di-n-butyl phthalate (DnBP), observed
from year 2005 onwards and the simultaneous increase
in concentrations of MCOP, a metabolite of diisononyl
phthalate (DiNP), could reflect changes in phthalates
Table 3 Adjusted Association Between Log-Transformed Phenol Urinary Concentrations and Sampling Conditions
among French Pregnant Women From Eden Cohort, 2002–2006 a
2,4-DCP 2,5-DCP Sum of Parabens BP3 BPA TCS
Sampling conditions n β P β P β P β P β P β P
Hour of sampling 191 0.40 f 0.44 f 0.04 f 0.13 f 0.14 f 0.36 f
< 7.00 AM 36 0 0 0 0 0 0
≥ 7.00 to 7.59 AM 75 0.17 0.51 0.07 0.86 0.02 0.96 −0.15 0.74 −0.39 0.05 0.46 0.35
≥ 8.00 to 9.59 AM 59 −0.14 0.60 −0.10 0.80 −0.14 0.79 0.10 0.82 −0.41 0.04 −0.29 0.61
After 10.00 AM 21 0.47 0.33 0.82 0.20 1.09 0.12 1.4 0.05 −0.58 0.04 0.49 0.57
P trend 0.73 0.46 0.42 0.11 0.03 0.95
Continuous b −0.03 0.65 0.04 0.72 0.07 0.38 0.14 0.31 −0.07 0.12 −0.06 0.62
Creatinine (g/l)c 191 0.33 0.05 0.36 0.14 0.59 0.04 0.82 <0.01 0.86 <0.01 0.20 0.53
Gestational age (weeks) 191 0.90 f 0.96 f 0.52 f 0.13 f <0.01 f 0.45 f
24-25 25 0 0 0 0 0 0
25-27 87 −0.04 0.90 −0.11 0.79 −0.41 0.28 −0.32 0.40 −0.06 0.75 −0.10 0.87
27-30 79 −0.12 0.70 −0.12 0.78 −0.39 0.33 0.35 0.44 0.37 0.07 −0.51 0.38
P trend 0.65 0.81 0.48 0.19 <0.01 0.26
Continuous d −0.08 0.29 −0.08 0.49 −0.09 0.41 0.15 0.27 0.14 0.01 −0.17 0.24
Day of sampling 191 0.51 f 0.49 f 0.86 f 0.79 f 0.91 f 0.76 f
Monday 28 0 0 0 0 0 0
Tuesday 54 0.52 0.15 0.82 0.10 0.32 0.48 0.17 0.74 −0.15 0.42 0.41 0.47
Wednesday 54 0.23 0.46 0.38 0.35 −0.03 0.95 0.45 0.41 −0.03 0.87 0.66 0.24
Thursday 31 0.40 0.27 0.58 0.26 0.32 0.57 0.27 0.69 −0.14 0.49 0.38 0.52
Friday 24 0.05 0.90 0.21 0.69 0.19 0.68 −0.12 0.82 −0.09 0.64 0.08 0.90
Season of sampling 191 0.65 f 0.28 f 0.64 f 0.45 f 0.35 f 0.93 f
Jan-March 59 0 0 0 0 0 0
April-June 49 −0.15 0.55 −0.46 0.23 −0.48 0.20 −0.63 0.15 −0.10 0.46 −0.25 0.59
July-Sept 38 −0.35 0.24 −0.74 0.11 −0.12 0.79 0.14 0.77 0.11 0.56 −0.03 0.96
Oct-Dec 45 −0.05 0.86 −0.03 0.93 −0.22 0.60 −0.31 0.48 0.25 0.19 −0.27 0.62
Duration of urine storage
at room temperature (hours)
191 0.22 f 0.04 f 0.29 f 0.54 f 0.42 f 0.33 f
< 3 57 0 0 0 0 0 0
3-4 51 −0.33 0.24 −0.71 0.09 0.67 0.13 −0.17 0.67 0.03 0.87 −0.16 0.74
4-5 32 0.14 0.72 0.23 0.70 0.15 0.78 −0.62 0.21 0.23 0.28 −1.1 0.12
> 5 51 −0.10 0.81 −0.31 0.58 −0.09 0.88 −0.07 0.91 0.27 0.19 −0.20 0.75
P trend 0.91 0.71 0.70 0.94 0.16 0.78
Continuous e −0.07 0.18 −0.12 0.07 −0.01 0.84 0.02 0.83 0.05 0.06 −0.02 0.86
a Linear regression models were corrected for over-representation of cases and adjusted for maternal age, bmi, parity, centre, education, occupation at the time of
urine collection and urine sampling conditions.
b Regression parameters are given for an increase by 1 in the sampling hour.
c Regression parameters are given for an increase by 1 g/l in urinary creatinine concentration.
d Regression parameters are given for an increase by 1 week.
e Regression parameters are given for an increase by 1 hour.
f
P of heterogeneity test
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Table 4 Phthalates Metabolites and Phenols Urinary Concentrations Among Pregnant Women From Eden and Pélagie Cohorts, France, 2002-2006
Correction/standardization applied to the biomarker concentrations
No correction
(Crude concentrations,
μg/l)a (1)
Case–control
sampling
only (μg/l)a (2)
Case–control sampling
and creatinine
(μg/g Cr)b (3)
Correction for
case–control
sampling and
standardization
for sampling conditions
including creatinine c
(μg/l)a (4)
Correction for
case–control
sampling and
standardization
for sampling conditions
excluding creatinine d
(μg/l)a (5)
Median
change(5–2)e
Correlation
standardized –
unstandardized
(5)(2) f
Compound n Median 25th 75th Median 25th 75th Median 25th 75th Median 25th 75th Median 25th 75th
Phthalate monoester
metabolites
MEHHP+MEOHP+
MECPP +MEHP (μmol/l)
287 0.36 0.18 0.62 0.37 0.17 0.61 0.32 0.19 0.53 0.53 0.29 0.86 0.58 0.32 1.06 + 56% 0.94
MiBP 287 50 29 97.5 45.9 30.2 84.0 45.7 28.0 71.9 59.2 39.0 101.5 64.7 41.2 119.3 + 41% 0.94
MBP 287 57.5 30.5 104 48.1 28.9 86.7 48.5 27.6 75.5 57.5 35.9 86.4 58.1 34.3 105.6 + 21% 0.96
MCCP 287 2.40 1.40 4.80 2.20 1.30 4.30 1.93 1.37 3.20 2.74 1.76 4.91 3.15 1.69 5.54 + 43% 0.94
MBzP 287 18.5 10.4 40.3 17.7 9.3 33.5 16.0 8.6 28.0 20.4 9.7 42.9 21.7 9.6 57.7 +23% 0.88
MEP 287 112 49.0 236 110 53.3 215 106 54.4 198 103 58.7 196 105 53.9 240 −5% 0.95
MCNP 287 1.90 1.10 3.40 1.70 1.10 3.00 1.59 1.15 2.51 2.89 2.05 5.00 3.06 1.89 5.63 +80% 0.95
MCOP 287 3.10 1.50 6.20 2.70 1.40 5.10 2.37 1.44 4.58 3.81 2.04 7.39 3.89 2.12 7.93 +44% 0.93
Phenols
2,4-DCP 191 0.90 0.50 1.60 0.90 0.50 1.50 0.78 0.51 1.48 0.78 0.47 1.51 0.77 0.49 1.59 −14% 0.98
2,5-DCP 191 10.30 4.10 26.8 10.2 4.10 26.50 8.88 4.27 24.4 6.73 3.08 23.3 6.37 2.92 25.6 −38% 0.95
Sum of Parabens
(μmol/l)
191 0.90 0.28 2.36 0.86 0.27 2.45 0.81 0.29 2.15 0.86 0.30 2.31 0.95 0.29 2.32 +10% 0.98
BP3 191 1.60 0.60 4.10 1.70 0.70 4.40 1.63 0.64 4.19 1.13 0.59 3.87 1.30 0.54 4.04 −24% 0.96
BPA 191 2.80 1.60 4.90 2.70 1.70 5.50 2.50 1.62 4.49 3.06 1.80 5.26 3.11 1.92 6.11 +15% 0.95
Triclosan 191 24.8 4.0 174 24.1 3.80 173 26.7 3.20 168.1 18.1 2.50 96.2 17.5 2.62 101.1 −27% 0.99
We applied correction factors of 0.66 and 0.72 to the monoethyl phthalate (MEP) and monobenzyl phthalate (MBzP) concentrations, respectively, because the analytic standards used were of inadequate purity.
a For metabolites of DEHP and sum of parabens, concentrations are reported in μmol/l.
b For metabolites of DEHP and sum of parabens, corrected concentrations are reported in μmol/g Creatinine. Correction for creatinine was performed by dividing biomarker concentrations by creatinine concentration.
c Results corrected for over-representation of cases according to Richardson et al. (2007) and standardized for all sampling conditions (including creatinine) using formula (1) in the methods section.
d Results corrected for over-representation of cases according to Richardson et al. (2007) and standardized for sampling conditions (excluding creatinine) using formula (1) in the methods section.
e Relative changes in the median concentration of urinary biomarkers between the estimates of column (5) and (2).
f Coefficient of correlation (Pearson) between non-standardized biomarkers levels corrected for the case–control sampling and concentrations corrected for the case–control sampling and standardized for all sampling
conditions excluding creatinine.
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usage in Europe. DiNP is used as substitute to replace
DEHP in many applications (ECPI, 2006): between 1999
and 2004, the proportion of DEHP to total phthalate
usage decreased, and the proportion of DiNP and
diisodecyl phthalate (DiDP) increased (ECPI, 2006).
However, we did not observe a temporal decrease in
DEHP metabolites.
Our results suggest that, like in other countries, French
pregnant women are exposed to a range of non-persist-
ent endocrine disruptors. MEP, MBP and MiBP were the
phthalates found at the highest concentrations. The con-
centrations of these phthalate metabolites and of MCPP
and the DEHP metabolites had the same magnitudes as
those observed among pregnant women elsewhere
[4,5,13,33,34]. MiBP concentrations reported in the USA
among pregnant women [13,33] were lower than in our
study (see Additional file 1: Figure S1). These geograph-
ical differences could be due to the fact that di-isobutyl
phthalate, of which MiBP is a major metabolite, is used
in Europe as a substitute of DnBP, banned by the Euro-
pean Union in personal care and cosmetic products [35].
Concerning phenols (see Additional file 1: Figure S2),
after adjustment for creatinine, BPA concentrations were
higher in our French population (median, 2.5 μg/g) than
those observed among pregnant women from Rotterdam
(median, 1.6 μg/g) [5], and from Cincinnati, Ohio (me-
dian at 16 gestational weeks, 1.7 μg/g) [36]. Mean values
were lower in Eden cohort (3.6 μg/g) than in a study in
Norway [4], where higher levels (creatinine-adjusted
mean of 5.9 μg/g) could be the consequence of a high
consumption of canned fish and seafood [4].
The concentrations of biomarkers issued from
biochemical assays cannot always be used in a straight-
forward way as an exposure variable in epidemiological
studies [19,37] and may require additional modeling
steps, just like for other exposure metrics. This can also
probably apply to descriptive (biomonitoring) studies.
Indeed, some degree of heterogeneity in sampling condi-
tions is unavoidable in observational settings. The 2-step
standardization method based on regression residuals
that we proposed constitutes a way to reduce undesirable
variability in biomarker urinary concentrations due to sam-
pling conditions, and allows more relevant comparisons be-
tween subjects and possibly between studies. This source of
variability can be seen as a source of measurement error in
exposure, which may have impacts in studies of the associ-
ation between biomarker levels and health, by impacting
the regression models estimates in either direction [38]
and/or confidence intervals. If we except the case of creatin-
ine, which can be seen as a proxy for a sampling condition
(time elapsed since the last void), and is very often corrected
for in descriptive or etiologic studies, our report is to our
knowledge one of the first attempts to limit variations in
phthalate and phenols biomarker levels due to variations in
urine sampling conditions in a descriptive setting using a
statistical approach.
In a further step, we suggest to use the standardized
biomarker concentration to characterize the relation
between biomarker levels and specific health outcomes
assessed in the same population [24]. Further develop-
ments of our approach that may be useful for such
etiological studies would be to acknowledge for the
variability in the regression coefficients corresponding to
the effect of sampling conditions on biomarkers
estimated in the measurement model (Eq. A.1, see Add-
itional file 1 statistical appendix). In particular, regression
models in which the standardized concentrations are
used as covariates should take this variability into
account. Incidentally, it can be noted that using unstan-
dardized (raw) levels in models not accounting for meas-
urement error due to variability in sampling conditions
can also impact on variance estimates and on bias; we
believe that an approach like ours, aiming at making
sources of measurement error explicit and at correcting
for them, is a step in the good direction. We chose to
standardize each biomarker level on all sampling condi-
tions simultaneously, but in future studies authors may
prefer to standardize only for those sampling conditions
that turn out to be associated with the considered
biomarker with a p value below a given level (say, p< 0.2).
As an alternative to using standardized biomarker
levels, some authors include sampling characteristics
as covariates in regression models describing associations
between biomarker levels and health outcome; this 1-step
approach may not allow efficiently standardizing
sampling conditions, as the parameter associated with
sampling conditions will reflect the association between
the sampling condition and the health outcome, and not
with the biomarker level [19]; our 2-step approach
allows to separately consider the influence of sampling
conditions on biomarker levels in a first step and to cor-
rect for it in a second step that does not consider the
health outcome; in a final step, the association between
standardized biomarker concentrations and the health
outcome can be characterized. There is a vast body of
literature on how to handle and try to correct measure-
ment error in covariates or health outcomes [39].
However, it is focused on situations in which there is
some knowledge either on the standard errors attached
to the error-prone variables or on the misclassification
rate, on situations in which validation data in which
both true and error-prone variables have been assessed
in a sub-populations, or in which instrumental variables
are available. These situations do not correspond to
ours, in which we do know and measure some factors
causing measurement error (the sampling conditions),
and empirically estimate the influence of these factors
on the mismeasured concentrations.
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The impact of sampling conditions on biomarker levels
was empirically estimated based on the association
observed in our data. An alternative would be to use a tox-
icokinetic model; however such models are not currently
available for most of the studied metabolites [40,41], in
particular for pregnant human subjects; only limited
data on the half-life or other toxicokinetic parameters of
the studied compounds are available, in populations
distinct from pregnant women, who are different from
non-pregnant women in terms of metabolism for specific
xenobiotics [42]. The lack of repeated assessment and of
information on timing of exposure did not allow to de-
velop such toxicokinetic modeling within our population.
Our two-step approach is to our knowledge original
although it follows a logic previously used in some
biomarkers studies [19], and also in other areas of the
epidemiologic and clinical literature, for example in
studies of lung function, in which results of a lung func-
tion test (e.g., FEV1) are standardized on gender and age,
to limit the impact of these (nuisance) factors.
Each pregnant woman provided only a single urine
sample, which probably limited the accuracy of our
estimates of the influence of sampling conditions. In
practice, many studies in the general population rely on
a single urine sample, and standardizing for sampling
conditions should also be attempted in this setting. We
assumed that adjustment for individual characteristics
such as age, occupation or smoking, made women
with different sampling conditions more comparable.
However, this approach might be limited by the existence
of unmeasured lifestyle or occupational factors
simultaneously associated with exposure and sampling
conditions. For instance, if women who collected a
urine sample early in the morning used more phthalate-
containing cosmetics than those who provided a urine
sample later in the morning, we might attribute to
variations in sampling hour differences actually due to
real exposure contrasts. Time since last exposure (and
amount of exposure) are also parameters likely to influ-
ence biomarker levels. These were not available in our
study; their assessment is challenging in observational
studies focused on compounds with several sources and
whose presence in consumers’ products is not known
by study participants. Moreover, time since last expos-
ure is likely to be shorter for subjects frequently
exposed to these compounds (and hence also possibly
more highly exposed to these compounds), so that
standardization for time since last exposure might
artificially decrease the between-subject contrasts in
exposure.
The efficiency of our approach may differ between
compounds. In the case of standardization for sampling
hour, for example, the approach is more likely to be
efficient for compounds in which biomarker levels in
urine follow a similar temporal pattern throughout the
day for most participants; such a situation is close to
what has been described for MEP [14]. For other
compounds for which temporal patterns strongly differ
between participants, as has been described for mono-
(2-ethyl-5-hydroxyhexyl) phthalate [14], our approach
is likely to be less efficient; in such cases, there may be
no efficient statistical alternative to collecting several
urine samples per day or 24-hour urine samples [14], at
least in a sub-population, after which measurement error
models [39,43] or toxicokinetic models (if available) could
be used. Similarly, if there is no consistent pattern of vari-
ation in exposure levels throughout the week, as seemed to
be the case in our population for most compounds, our
approach is unlikely to correct for daily variations in
exposure and thus to make biomarker levels more
representative of the weekly exposure average.
For the above-mentioned reasons, some error in our esti-
mates of the influence of sampling conditions on biomarker
concentration is expected, so that we cannot exclude that
the standardized concentrations sometimes entail more bias
than the original measure [44]. Consequently, studies on
exposure-response relations using an approach such as ours
should also report the association between the uncorrected
biomarker concentrations and the health outcome, in
addition to the association relying on standardized bio-
marker concentrations [24]. Furthermore, information on
sampling conditions such as those considered here (in
addition, whenever relevant, to batch number, assay date,
and information on any deviation from the planned proto-
col) should be collected for all study subjects so that their
possible impact can be characterized and if required cor-
rected for.
Conclusions
In conclusion, hour of sampling was associated with the
urinary concentrations of select phthalate metabolites and
phenols. This confirms the relevance for studies aiming to
characterize the health effect of compounds with a short
half-life such as phthalates and phenols to rely on repeated
biomarker assays. Our approach used to standardize con-
centrations of biomarkers in urine specimens collected
under varying conditions (e.g., time of day) could be rele-
vant for future studies aiming at describing the urinary con-
centrations of biomarkers, or their influence on human
health outcomes.
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Additional file 2: Table S1. Limits of Detection of Urinary Phthalates
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Pregnant Women from Eden and Pelagie Cohorts, 2002–2006. Table S2.
Correlation coefficients between Phthalates Monoesters Metabolites and
Phenols Crude Urinary Concentrations Among French Pregnant Women
from Eden and Pelagie Cohorts, 2002–2006.Table S3. Adjusted
Association Between Log-Transformed Phthalate Monoester Metabolites
Urinary Concentrations and Characteristics of French Pregnant Women
From Eden and Pélagie Cohorts, 2002–2006. Linear Regression Models
Were Corrected for Over-Representation of Cases and Adjusted for
Maternal age, BMI, Parity, Centre, Education, Occupation and Urine
Sampling Conditions. Table S4. Adjusted Association Between Log-
Transformed Phenol Urinary Concentrations and Characteristics of French
Pregnant Women from Eden and Pelagie Cohorts, 2002–2006. Linear
Regression Models Were Corrected for Over-Representation of Cases and
Adjusted for Maternal age, BMI, Parity, Centre, Education, Occupation and
Urine Sampling Conditions. Figure S1. Median Values of Urinary
Phthalate Metabolites (μg/l) in Selected Publications Among Pregnant
Women. Figure S2. Median Values of Urinary Phenols (μg/l) in Selected
Publications Among Pregnant Women.
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